Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SGMO

Sangamo Therapeutics Inc

Dec 06 • 04:00PM ET

0.4481

Dollar change -0.0028
Percentage change -0.62	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.44	Insider Own	10.78%	Shs Outstand	166.79M	Perf Week	8.97%
Market Cap	79.47M	Forward P/E	-	EPS next Y	-0.51	Insider Trans	-23.89%	Shs Float	158.23M	Perf Month	1.47%
Income	-249.51M	PEG	-	EPS next Q	-0.26	Inst Own	58.08%	Short Float / Ratio	6.52% / 4.92	Perf Quarter	-52.95%
Sales	201.42M	P/S	0.39	EPS this Y	-9.52%	Inst Trans	8.57%	Short Interest	10.31M	Perf Half Y	-65.53%
Book/sh	0.76	P/B	0.59	EPS next Y	62.45%	ROA	-61.33%	Target Price	2.79	Perf Year	-87.34%
Cash/sh	0.74	P/C	0.60	EPS next 5Y	-	ROE	-112.37%	52W Range	0.29 - 3.76	Perf YTD	-85.73%
Dividend	-	P/FCF	-	EPS past 5Y	-12.22%	ROI	-146.86%	52W High	-88.07%	Beta	0.98
Dividend %	-	Quick Ratio	3.04	Sales past 5Y	32.37%	Gross Margin	89.77%	52W Low	53.93%	ATR	0.06
Employees	478	Current Ratio	3.04	Sales Q/Q	-64.48%	Oper. Margin	-53.28%	RSI (14)	51.52	Volatility	14.98% 14.48%
Optionable	Yes	Debt/Eq	0.26	EPS Q/Q	-74.81%	Profit Margin	-123.87%	Rel Volume	0.37	Prev Close	0.45
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Nov 01 AMC	Payout	-	Avg Volume	2.10M	Price	0.45
Recom	2.20	SMA20	16.52%	SMA50	-5.98%	SMA200	-62.66%	Volume	774,212	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6 → $2
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform	$5 → $1.50
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform	$16
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $5
Jun-13-22	Resumed	Wedbush	Neutral	$5
May-04-21	Initiated	RBC Capital Mkts	Outperform	$22
Jan-07-21	Resumed	Guggenheim	Neutral	$16
Jan-06-21	Initiated	Stifel	Hold	$16
Dec-16-20	Resumed	H.C. Wainwright	Buy	$25
Sep-08-20	Initiated	BofA Securities	Buy	$20
Jul-07-20	Initiated	SunTrust	Buy	$22
Aug-26-19	Initiated	H.C. Wainwright	Buy	$16
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy	$24
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy	$17
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral	$30 → $4
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral

Show Previous Ratings

Nov-03-23 05:03PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:15AM	Sangamo to cut jobs again with planned business overhaul (BioPharma Dive) -22.14%
Nov-01-23 07:05PM	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update (GuruFocus.com) -6.25%
04:13PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Business Wire)
10:02AM	Loading…
Oct-26-23 10:02AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 04:15PM	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Business Wire)
Oct-24-23 02:01AM	Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Sep-20-23 04:15PM	Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit (Business Wire)
Aug-25-23 01:38PM	Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases (InvestorPlace) -12.49%
Aug-08-23 05:30PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:26PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results (Business Wire)
Aug-01-23 04:15PM	Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast (Business Wire)
Jul-20-23 08:05AM	Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing (Business Wire)
07:08AM	Loading…
Jul-19-23 07:08AM	The past five years for Sangamo Therapeutics (NASDAQ:SGMO) investors has not been profitable (Simply Wall St.)
Jul-17-23 08:05AM	Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids (Business Wire)
Jun-29-23 08:05AM	Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease (Business Wire)
Jun-28-23 09:20AM	FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing (Zacks)
Jun-14-23 08:16AM	We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate (Simply Wall St.)
May-22-23 08:05AM	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for Isaralgagene Civaparvovec for the Treatment of Fabry Disease (Business Wire) +5.43%
May-18-23 07:04AM	Industry Analysts Just Upgraded Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Forecasts By 52% (Simply Wall St.)
May-16-23 08:00AM	Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer (Business Wire)
May-02-23 04:30PM	Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -9.27%
06:03AM	Analysts Just Made A Huge Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts (Simply Wall St.)
Apr-26-23 05:28PM	Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results (Business Wire)
Apr-25-23 02:39PM	Biogen shifts gene therapy focus as it builds $200M facility in RTP (American City Business Journals)
Apr-21-23 04:58AM	Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength? (Zacks)
Apr-19-23 04:15PM	Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast (Business Wire)
Apr-17-23 07:38AM	Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Shares Lagging The Industry But So Is The Business (Simply Wall St.) +5.45%
06:30AM	Loading…
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Mar-23-23 06:09AM	The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership (American City Business Journals)
Mar-21-23 09:35AM	Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-20-23 12:25PM	Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo (Benzinga)
Mar-10-23 09:35AM	Sangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Feb-25-23 08:26AM	In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Feb-23-23 05:36PM	Sickle-cell gene therapy developer stops program, cuts half of staff (American City Business Journals)
11:57AM	Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical Benefit (Benzinga)
Feb-22-23 05:25PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
03:01PM	Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease (Business Wire)
09:35AM	Here's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks (Zacks)
Feb-21-23 09:01AM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast (Business Wire) -7.49%
Feb-16-23 10:01AM	Sangamo Therapeutics (SGMO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-13-23 09:55AM	Here's Why Sangamo (SGMO) Looks Ripe for Bottom Fishing (Zacks)
Feb-10-23 11:01AM	Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week (Motley Fool)
Jan-30-23 07:10PM	7 CRISPR Stocks With the Best Long-Term Potential (InvestorPlace) -5.03%
Dec-06-22 06:02AM	Sangamo Therapeutics (NASDAQ:SGMO) investors are sitting on a loss of 78% if they invested five years ago (Simply Wall St.)
Nov-09-22 05:31AM	Sangamo Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-03-22 05:55PM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results (Business Wire)
Oct-27-22 04:15PM	Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast (Business Wire)
Oct-14-22 09:49AM	10 Best Gene Editing Stocks To Buy (Insider Monkey)
Oct-12-22 08:55AM	Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate (Benzinga)
03:01AM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients (Business Wire)
Sep-23-22 12:02PM	Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold (Benzinga)
Sep-18-22 09:11AM	Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Aug-30-22 08:50AM	Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile (Benzinga)
06:00AM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients (Business Wire)
Aug-29-22 09:55AM	Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect? (Zacks)
Aug-12-22 09:55AM	Wall Street Analysts Predict a 106% Upside in Sangamo (SGMO): Here's What You Should Know (Zacks) +8.76%
Aug-04-22 05:45PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results (Business Wire)
Jul-28-22 04:15PM	Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast (Business Wire)
Jul-21-22 08:05AM	European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation (Business Wire)
Jul-18-22 09:21AM	Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-07-22 08:55AM	Shareholders in Sangamo Therapeutics (NASDAQ:SGMO) are in the red if they invested a year ago (Simply Wall St.) +8.65%
Jun-01-22 04:30PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire)
May-08-22 08:09AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Are Reducing Their Forecasts For This Year (Simply Wall St.)
May-05-22 05:45PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.11%
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results (Business Wire)
May-04-22 06:35PM	Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-22 04:30PM	Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) +6.99%
Apr-28-22 04:15PM	Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast (Business Wire)
Apr-21-22 04:30PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire) -6.67%
Apr-11-22 08:59AM	What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry? (Simply Wall St.) -5.10%
Mar-30-22 06:40AM	Strength Seen in Sangamo (SGMO): Can Its 9.6% Jump Turn into More Strength? (Zacks) -5.57%
Mar-29-22 08:05AM	Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation (Business Wire) +9.60%
Feb-28-22 05:00PM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire)
Feb-24-22 06:20PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.13%
04:01PM	Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights (Business Wire)
Feb-17-22 04:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast (Business Wire)
Feb-08-22 11:32AM	Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation (Simply Wall St.)
06:52AM	Sangamo Therapeutics Shares Updated Interim Data From Fabry Disease Gene Therapy Trial (Benzinga)
Feb-07-22 06:00PM	Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated -Gal A Enzyme Activity in Patients With Fabry Disease (Business Wire)
Jan-21-22 05:38PM	PrairieView Partners, LLC Buys iShares Short-Term National Muni Bond ETF, Avantis Core ... (GuruFocus.com)
Jan-13-22 01:38PM	McGuire Investment Group, LLC Buys SPDR Bloomberg 1-3 Month T-Bill ETF, WisdomTree Floating ... (GuruFocus.com)
Jan-06-22 08:00AM	Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo (Business Wire)
Jan-04-22 05:00PM	Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference (Business Wire) -5.12%
Dec-20-21 05:29PM	BioMarin settles trade secrets 'misunderstanding' with former employee (American City Business Journals)
Dec-13-21 10:54AM	Pfizer (PFE) Gets Approval for New Eczema Drug in Europe (Zacks) -5.69%
Dec-12-21 04:30PM	Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy (Business Wire)
09:00AM	Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease (Business Wire)
Dec-10-21 09:34AM	Investors in Sangamo Therapeutics (NASDAQ:SGMO) have made a strong return of 139% over the past five years (Simply Wall St.) -5.04%
Nov-22-21 07:00AM	Organogenesis Appoints Prathyusha Duraibabu to Board of Directors (GlobeNewswire)
Nov-18-21 05:54PM	BioMarin says ex-employee downloaded trade secrets. He says it's a misunderstanding. (American City Business Journals)
Nov-09-21 08:30AM	Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences (Business Wire)
Nov-08-21 10:13AM	Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a Bet (Zacks)
Nov-04-21 10:01PM	Sangamo Therapeutics, inc (SGMO) Q3 2021 Earnings Call Transcript (Motley Fool) +19.15%
05:20PM	Why Did Sangamo Stock Jump 20% Today? (Benzinga)

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOGEN INC.	10% Owner	Sep 26	Sale	0.50	6,000,000	3,000,000	17,652,466	Sep 28 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SGMO

Sangamo Therapeutics Inc

Upgrade your FINVIZ experience